Oncology Corporate Profile
Founded in 2004, Kinex is led by a strong, experienced Management Team and Board of Directors with a track record of achieving value-creating milestones and cumulative experience of over 150 years in both the pharmaceutical and biotechnology industries. This includes the filing of 11 NDAs and more than 20 INDs with the Food and Drug Administration and the development of 10 marketed products, including several blockbusters. Kinex has utilized the proprietary platform technologies Mimetica™, Opal™, and Orascovery™ to discover new compounds and to build a pipeline of drug candidates with unique mechanisms that address unmet medical needs with large market potential.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|KX02||dual src/pre-tubulin inhibitor||Glioma||II|
|KX01||tyrosine kinase inhibitor||Acute Myelogenous Leukemia (AML)||I|